

## Novel Agents in the Treatment of Lung Cancer

### Sponsorship and CME Credit

This journal CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical Communications, Inc. is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.

InforMEDical Communications, Inc. designates this continuing medical education activity for a maximum of 4 credit hours in Category 1 credit toward the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/ she actually spends on the educational activity.

This journal CME activity is valid for release in June 2004. The date of expiration is June 2006.

### Educational Need

Understanding of lung cancer biology has increased dramatically over the past decade, leading to the development of several novel agents that are now in clinical trials. However, it is not clear how these agents will be integrated into the current approach to patients with non-small cell lung cancer. A program that surveys and summarizes where we are with these molecularly targeted agents will help clinicians understand more about the status and potential uses of new agents as they plan future therapies.

### Educational Objectives:

After reading this supplement, participants should be able to:

- Review important aspects of lung cancer biology as they pertain to novel treatments.
- Discuss the rationale for identifying a target as therapeutically important.
- Appreciate the role of molecularly targeted agents in the current treatment of advanced lung cancer.
- Assess the ongoing trials using these agents and the impact that such studies will have on future care.

This supplement to Clinical Cancer Research is designed to meet the educational needs of oncologists and pulmonary specialists who wish to learn more about novel approaches to the treatment of lung cancer.

### Faculty Disclosure

The conference faculty have reported the following financial relationships with commercial pharmaceutical, device or biotechnology companies:

**Dr. Alex A. Adjei:** Aventis: research grant; Bristol-Myers Squibb: clinical trials support; Eli Lilly: clinical trials support; Pharmacia: research grant. **Dr. Paul A. Bunn, Jr.:** AstraZeneca: advisor/ consultant, honorarium; Aventis: advisor/consultant, honorarium; Bristol-Myers Squibb: advisor/ consultant, honorarium; Eli Lilly: advisor/consultant, honorarium, research grant; Genentech: honorarium; Pharmacia: advisor/consultant, honorarium, research grant; Millenium: consultant. **Dr. Raymond N. DuBois:** Abbott: consultant; Merck: research grant; Nestec: research grant; Novartis: consultant; Pharmacia: research grant; Salix: consultant. **Dr. David R. Gandara:** Millenium: consultant. **Dr. Giuseppe Giaccone:** Nothing to disclose. **Dr. Ramaswamy Govindan:** AstraZeneca: honorarium, research grant; Aventis: honorarium, research grant; Eli Lilly: honorarium, research grant; GlaxoSmithKline: honorarium, research grant; Pharmacia: honorarium, research grant. **Dr. Roy S. Herbst:** Nothing to disclose. **Dr. Bruce E. Johnson:** Nothing to disclose. **Dr. Fadlo R. Khuri:** AstraZeneca: research grant; Johnson & Johnson: research grant; Schering-Plough: research grant. **Dr. Thomas J. Lynch:** AstraZeneca: research grant, Speakers' Bureau; Aventis: consultant, Speakers' Bureau; Bristol-Myers Squibb: research grant, Speakers' Bureau; Eli Lilly: research grant, Speakers' Bureau; Merck: consultant; SmithKline Beecham: research grant, Speakers' Bureau. **Dr. Roman Perez-Soler:** Amgen: consultant, research support, stockholder; AstraZeneca: consultant, research support, stockholder; Genentech: consultant, research

support, stockholder; Novartis: consultant, research support, stockholder; OSI: consultant, research support, stockholder. **Dr. Rafael Rosell:** Nothing to disclose. **Dr. Eric K. Rowinsky:** Abgenix: research grant; Aventis: research grant; Danek: research grant; GlaxoSmithKline: research grant; Human Genome Sciences: research grant; Imclone: research grant; Mederex: research grant; OSI: research grant; Pfizer: research grant; Wyeth: research grant. **Dr. Alan B. Sandler:** AstraZeneca: consultant, research grant, Speakers' Bureau; Aventis: consultant, research grant, Speakers' Bureau; Bristol-Meyers Squibb: consultant, research support, Speakers' Bureau; Eli Lilly: consultant, research grant, Speakers' Bureau; Genentech: consultant, research grant, Speakers' Bureau; OSI: consultant, research grant, Speakers' Bureau; Pfizer: consultant, research grant, Speakers' Bureau. **Dr. Giorgio V. Scagliotti:** Nothing to disclose. **Dr. Joan H. Schiller:** AstraZeneca: advisory board, research grant; Cell Pathways: advisory board, research grant; Eli Lilly: advisory board, research grant; Genentech: advisory board, research grant. **Dr. Geoffrey I. Shapiro:** Aventis: consultant, research grant. **Dr. Mark A. Socinski:** Amgen: research grant, Speakers' Bureau; AstraZeneca: research grant, Speakers' Bureau; Bristol-Meyers Squibb: research grant, Speakers' Bureau; Eli Lilly: research grant, Speakers' Bureau; Pharmacia: research grant, Speakers' Bureau.